Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials.

Détails

Ressource 1Télécharger: BIB_6347895092A8.P001.pdf (353.00 [Ko])
Etat: Public
Version: de l'auteur⸱e
ID Serval
serval:BIB_6347895092A8
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Institution
Titre
Vaccination Strategies against Highly Pathogenic Arenaviruses: The Next Steps toward Clinical Trials.
Périodique
Plos Pathogens
Auteur⸱e⸱s
Olschläger S., Flatz L.
ISSN
1553-7374 (Electronic)
ISSN-L
1553-7366
Statut éditorial
Publié
Date de publication
2013
Volume
9
Numéro
4
Pages
e1003212
Langue
anglais
Notes
Publication types: Journal ArticlePublication Status: ppublish. PDF type: Review
Résumé
Vaccination is one of the most valuable weapons against infectious diseases and has led to a significant reduction in mortality and morbidity. However, for most viral hemorrhagic fevers caused by arenaviruses, no prophylactic vaccine is available. This is particularly problematic as these diseases are notoriously difficult to diagnose and treat. Lassa fever is globally the most important of the fevers caused by arenaviruses, potentially affecting millions of people living in endemic areas, particularly in Nigeria. Annually, an estimated 300,000 humans are infected and several thousands succumb to the disease. The successful development of the vaccine "Candid#1" against Junin virus, the causative agent of Argentine hemorrhagic fever, proved that an effective arenavirus vaccine can be developed. Although several promising studies toward the development of a Lassa fever vaccine have been published, no vaccine candidate has been tested in human volunteers or patients. This review summarizes the immunology and other aspects of existing experimental arenavirus vaccine studies, discusses the reasons for the lack of a vaccine, and proposes a plan for overcoming the final hurdles toward clinical trials.
Pubmed
Web of science
Open Access
Oui
Création de la notice
31/05/2013 16:46
Dernière modification de la notice
20/08/2019 14:19
Données d'usage